HRL enters the week in a difficult spot — the stock has shed 15% over the past month to $20.79, and short sellers have quietly been building positions into the weakness.
The most telling development this week is the sharp jump in short interest. Borrowed shares rose roughly 20% in a single week, lifting SI to 3.8% of the free float. That move is almost entirely concentrated in a step-change that appeared around September 9, when shares short climbed from roughly 17.4 million to 20.8 million in a matter of days. The stock's latest print is nearly 25% below the Street's consensus target of $26.13, which creates a visible gap — but the direction of short-side positioning suggests traders are not yet convinced a reversal is imminent. Despite the rebuild, the borrow market itself remains loose: availability is running at 1,353% — far above its 52-week trough of 282% — with cost to borrow at just 0.41%, barely above the floor. Shorts face no squeeze pressure at these levels, and the ORTEX short score of 40.7 ranks in the 34th percentile, reflecting a modest but not extreme bearish skew.
Options positioning, by contrast, tells a more relaxed story. The put/call ratio has eased to 0.39, roughly half a standard deviation below its 20-day average of 0.44. That places it closer to its 52-week low of 0.30 than its high of 0.60, and well below the protective hedging levels seen in late August and early September, when the PCR briefly climbed above 0.55. The divergence is notable: shorts are rebuilding, but options traders are not piling into downside protection at the same pace.
The Street is broadly neutral, and has been for some time. BNP Paribas trimmed its target from $27 to $26 at the end of August following the earnings print, while JP Morgan moved in the other direction just two weeks earlier, nudging its target to $26 from $25 while keeping a Neutral rating. The cluster of $25–$27 targets across BNP Paribas, BofA, and JPM reflects a consensus that fair value is meaningfully higher than today's price — but nobody is willing to say so with conviction. The bull case rests on Hormel's branded portfolio, self-help potential, and a forward earnings yield that has risen as the stock has fallen, with the P/E now at 13.7x and the dividend score ranking in the 99th percentile, an unusually high reading. The bear case is harder to dismiss after earnings: on August 27, the stock fell 9% in a single day, extending to an 8.6% loss over the following five days. The next earnings event is scheduled for December 3.
Ownership provides useful context. The Hormel Foundation holds approximately 46.6% of shares outstanding, a controlling stake that has not changed. Passive flows are gently building — Dimensional Fund Advisors added over 2.5 million shares through August, Norges Bank added 3.2 million through June, and Goldman Sachs grew its position by 1.4 million. These are slow-moving, index-adjacent flows rather than active conviction calls. On the insider side, the only open-market transaction in the past 90 days was a discretionary sale by director Gary Bhojwani in July — 20,200 shares at roughly $24.51, a $495,000 trade with no 10b5-1 plan attached. At a price more than 15% below the sale price, that timing looks unflattering in hindsight, though a single director sale is a thin signal on its own.
Peers have not provided much cover. GIS fell 2.9% on the week, CPB dropped 1.8%, and CAG lost 1.6%. SMPL was the worst performer among the group, off 8.6%. MDLZ was the lone bright spot, up 0.8%. The sector-wide drift lower reflects continued pressure on packaged foods broadly, leaving Hormel with limited peer-driven tailwinds to lean on. With December earnings still more than eleven weeks away, the next near-term pivot will likely be whether short interest continues to build on the September step-change, or whether the discount to analyst targets begins to attract fresh buying.
See the live data behind this article on ORTEX.
Open HRL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
